Publicacións en colaboración con investigadores/as de Yale Cancer Center (6)

2022

  1. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk

    Prostate Cancer and Prostatic Diseases, Vol. 25, Núm. 2, pp. 274-282

  2. Improved Survival with Enzalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer

    Journal of Clinical Oncology, Vol. 37

2021

  1. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses

    The Journal of urology, Vol. 205, Núm. 5, pp. 1361-1371

  2. Reply by Authors

    The Journal of urology, Vol. 205, Núm. 5, pp. 1371

2020

  1. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

    Journal of Clinical Oncology

2018

  1. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer

    New England Journal of Medicine, Vol. 379, Núm. 21, pp. 2027-2039